natgillin/translations-raw huggingface dataset:
At the 4-week follow-up visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pre-treatment levels.
Na kontrolnom pregledu nakon 4 tjedna (4 tjedna nakon završetka primjene ivakaftora), prosječne vrijednosti koncentracije klorida u znoju za svaku skupinu kretale su se prema razinama prije liječenja.
At the base of cat’s head, part the hair until the skin is visible.
Na bazi mačje glave razdvojite dlaku dok ne vidite kožu.
At the beginning of the fourth week, you should take Leganto 8 mg (package marked with ”Week 4“).
Na početku četvrtkog tjedna primijenite Leganto 8 mg/24 h (pakiranje označeno “Tjedan 4”).
At the beginning of the fourth week, you should take Neupro 8 mg (package marked with ”Week 4“).
Na početku četvrtkog tjedna primijenite Neupro 8 mg/24 h (pakiranje označeno “Tjedan 4”).
At the beginning of the preventive therapy with Telmisartan Teva Pharma 80 mg, blood pressure should be frequently monitored.
Na početku preventivnog liječenja s Telmisartanom Teva Pharma od 80 mg, krvni tlak treba redovito pratiti.
At the beginning of the second week, you should take Leganto 4 mg (package marked with “Week 2“).
Na početku drugog tjedna primijenite Leganto 4 mg/24 h (pakiranje označeno “Tjedan 2”).
At the beginning of the second week, you should take Neupro 4 mg (package marked with “Week 2“).
Na početku drugog tjedna primijenite Neupro 4 mg/24 h (pakiranje označeno “Tjedan 2”).
At the beginning of the third week, you should take Leganto 6 mg (package marked with “Week 3“).
Na početku trećeg tjedna primijenite Leganto 6 mg/24 h (pakiranje označeno “Tjedan 3”).
At the beginning of the third week, you should take Neupro 6 mg (package marked with “Week 3“).
Na početku trećeg tjedna primijenite Neupro 6 mg/24 h (pakiranje označeno “Tjedan 3”).
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common.
Na početku liječenja ili povećanja doze nuspojave, nuspojave poput pospanosti, umora i omaglice, mogu se češće javiti. .
At the beginning of treatment side effects are common but in general they become less with further treatment.
Na početku liječenja nuspojave su česte, ali obično nestaju s daljnjim liječenjem.
At the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills/rigors.
U početku liječenja lijekom IntronA možete imati reakciju nalik gripi, s vrućicom, umorom, glavoboljom, bolovima u mišićima i zglobovima te zimicom/tresavicom.
At the beginning of your infusion you will receive Flebogamma DIF at a slow rate (0.01-0.02 ml/kg/min).
Na početku infuzije primit ćete lijek Flebogamma DIF malom brzinom (0,01 - 0,02 ml/kg/min).
At the conclusion of Part I, JIA ACR 30/50/70/90 responses were 89.4%, 83.0%, 62.2%, and 26.1%, respectively.
Po završetku dijela I, udjeli odgovora JIA ACR 30/50/70/90 iznosili su 89,4%, 83,0%, 62,2% odnosno 26,1%.
At the discretion of the physician, the infusion may be continued for a total duration of four hours.
Prema odluci liječnika, infuzija se smije nastaviti do ukupnog trajanja od četiri sata.
At the discretion of the physician, the patient may self-administer the dose for maintenance dosage regimens administered subcutaneously.
Prema odluci liječnika, bolesnik si tijekom terapije održavanja može sam primjenjivati dozu lijeka supkutano.
At the discretion of the veterinarian, infested dogs should be treated with an adulticide to remove adult heartworms.
Prema procijeni veterinara psi koji imaju invaziju srčanog crva trebaju se liječiti adulticidom kako bi se odrasle jedinke uklonile.
At the dose of 1250 mg/m2 on day 14 with administration after food intake, the peak plasma concentrations (Cmax in µg/ml) for capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively.
U dozi od 1250 mg/m2 uzetoj nakon jela 14. dana liječenja vršne koncentracije kapecitabina, 5'-DFCR, 5'- DFUR, 5-FU i FBAL u plazmi (Cmax u µg/ml) iznosile su 4,67; 3,05; 12,1; 0,95 i 5,46.
At the dose of 1250 mg/m2 on day 14 with administration after food intake, the peak plasma concentrations (Cmax in μg/ml) for capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively.
U dozi od 1250 mg/m2 uzetoj nakon jela 14. dana liječenja vršne koncentracije kapecitabina, 5'-DFCR, 5'- DFUR, 5-FU i FBAL u plazmi (Cmax u µg/ml) iznosile su 4,67; 3,05; 12,1; 0,95 i 5,46.
At the doses recommended for use in the treatment of essential thrombocythaemia, anagrelide may potentiate the effects of other medicinal products that inhibit or modify platelet function e.g. acetylsalicylic acid.
U dozama preporučenim za primjenu u liječenju esencijalne trombocitemije anagrelid može pojačati učinke drugih lijekova koji inhibiraju ili mijenjaju funkciju trombocita, npr. acetilsalicilna kiselina.
At the end of 2 years follow-up after treatment, most patients had returned to baseline normative growth curve percentiles for weight and height (mean weight percentile was 64% at baseline and 60% at 2 years post-treatment; mean height percentile was 54% at baseline and 56% at 2 years post-treatment).
Na kraju dvogodišnjeg praćenja nakon liječenja većina se bolesnika vratila na početne percentile normativne krivulje porasta tjelesne težine i visine (srednja vrijednost percentile težine bila je 64% na početku i 60% dvije godine nakon završetka liječenja; srednja vrijednost percentile visine bila je 54% na početku i 56% dvije godine nakon završetka liječenja).
At the end of 24 hours of use, or after 80 doses have been delivered, remove IONSYS by gently lifting the red tab and loosening it from the skin application site.
Na kraju 24 sata primjene, ili nakon što je isporučeno 80 doza, uklonite IONSYS tako da nježno podignete crveni jezičak i olabavite ga s mjesta primjene na koži.
At the end of 24 weeks post-treatment follow-up, mean decrease from baseline in weight and height percentiles were still 3 percentiles and 7 percentiles, respectively, and 20% of the children continued to have inhibited growth (growth velocity < 3rd percentile).
Na kraju 24-tjednog praćenja nakon završetka liječenja srednje vrijednosti su još uvijek bile smanjene u odnosu na početak ispitivanja za prosječno 3 percentila na krivulji težine te za prosječno 7 percentila na krivulji rasta, dok je 20% djece i dalje imalo usporen rast (brzina rasta < 3. percentile).
At the end of 5 years, all patients had HBV DNA levels that were undetectable or lower than pre-treatment levels.
Nakon 5 godina u svih bolesnika razine HBV DNA bile su nemjerljive ili niže nego prije početka liječenja.
At the end of a 4-weeks dosing cycle of Vantobra (170 mg/1.7 ml twice daily) in cystic fibrosis patients, maximum tobramycin plasma concentrations (Cmax) of 1.27 ± 0.81 µg/ml were reached at approximately one hour after inhalation.
Na kraju četverotjednog ciklusa doziranja tijekom kojeg su bolesnici s cističnom fibrozom primali lijek Vantobra (170 mg/1,7 ml - dva puta dnevno), najviša koncentracija tobramicina u plazmi (Cmax) u vrijednosti od 1,27 ± 0,81 µg/ml dosegnuta je otprilike jedan sat nakon inhalacije.
At the end of both studies, patients were followed in the extension phase for up to 14 months.
Po završetku oba ispitivanja, bolesnici su praćeni tijekom faze produljenje u trajanju od 14 mjeseci.
At the end of each dosing interval, CTX reductions were partially attenuated from maximal reduction of ≥ 87% to approximately ≥ 45% (range 45-80%), reflecting the reversibility of Prolia’s effects on bone remodelling once serum levels diminish.
Na kraju svakog razdoblja doziranja smanjenja CTX su djelomično oslabljena s maksimalnog smanjenja od ≥ 87% na približno ≥ 45% (raspon 45-80%), odražavajući reverzibilnost učinaka lijeka Prolia na preoblikovanje kostiju jednom nakon što je smanjenja vrijednosti razina u serumu.
At the end of infusion, wash the bag 2 or 3 times with a physiological solution using a sterile technique, in order to completely administer Zalmoxis.
Na kraju infuzije isperite vrećicu 2 ili 3 puta fiziološkom otopinom primjenom sterilne tehnike kako bi se Zalmoxis potpuno primijenio.
At the end of maintenance, the mean UPDRS part III score had improved by 7.0 points in rotigotine-treated patients (baseline 29.6), and by 3.9 points in the placebo-group (baseline 32.0).
Na kraju terapije održavanja, prosječna ocjena prema UPDRS (dio III) ljestvici popravila se za 7 bodova u bolesnika koji su liječeni rotigotinom (početno 29,6) te za 3,9 bodova u placebo skupini (početno 32,0).
At the end of the 24-week main treatment period, 52.3% of the lixisenatide patients achieved an HbA1c less than 7 % compared to 26.4% in the placebo group.
Na kraju osnovnog 24-tjednog razdoblja liječenja u 52,3% bolesnika na liksisenatidu vrijednost HbA1c bila je manja od 7%, u usporedbi s 26,4% bolesnika na placebu.
At the end of the 28 week treatment period the dose was 65 units/day and 51 units/day, for patients receiving placebo and Trulicity 1.5 mg, respectively.
Na kraju 28-tjednog razdoblja liječenja, doza je bila 65 jedinica/dan za bolesnike koji su primali placebo te 51 jedinica/dan za bolesnike liječene lijekom Trulicity 1,5 mg.
At the end of the first year (week 52 in OSLER and week 48 in OSLER-2), patients were eligible to enter the all Repatha period in which all patients could receive open-label Repatha for either another 4 years (OSLER) or 1 year (OSLER-2).
Na kraju prve godine (52. tjedan u OSLER i 48. tjedan u OSLER-2), bolesnici su stekli uvjete za ulazak u Repatha razdoblje u kojem su svi bolesnici mogli otvoreno (open-label) uzimati lijek Repatha bilo još 4 godine (OSLER) ili 1 godinu (OSLER-2).
At the end of the follow-up period (actual median follow-up time of 96 months), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2,2%).
Na kraju perioda praćenja (stvarni medijan vremena praćenja iznosio je 96 mjeseci), alopecija je i dalje bila prisutna u 29 bolesnika u TAC skupini (3,9%) i 16 bolesnika u FAC skupini (2,2 %).
At the end of the follow-up period (actual median follow-up time of 96 months), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).
Na kraju perioda praćenja (stvarni medijan vremena praćenja iznosio je 96 mjeseci), alopecija je i dalje bila prisutna u 29 bolesnika u TAC skupini (3,9%) i 16 bolesnika u FAC skupini (2,2%).
At the end of the follow-up period actual median follow-up time of 96 months), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).
kupini.Na kraju perioda praćenja (stvarni medijan vremena praćenja iznosio je 96 mjeseci), alopecija je i dalje bila prisutna u 29 bolesnika u TAC skupini (3,9%) i 16 bolesnika u FAC skupini (2,2%).
At the end of the follow-up period(actual median follow-up time of 96 months), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%).
Na kraju perioda praćenja (stvarni medijan vremena praćenja iznosio je 96 mjeseci), alopecija je i dalje bila prisutna u 29 bolesnika u TAC skupini (3,9%) i 16 bolesnika u FAC skupini (2,2 %).
At the end of the main 24-week treatment period, 32.2% of the patients having a positive antibody status had an antibody concentration above the lower limit of quantification, and at the end of the entire 76-week treatment period, 44.7% of the patients had an antibody concentration above the lower limit of quantification.
Na kraju osnovnog tjednog razdoblja liječenja u 32,2% bolesnika koji su imali pozitivan nalaz protutijela, koncentracija je bila iznad donje granice mjerljivosti, dok je na kraju ukupnog 76-tjednog razdoblja liječenja koncentraciju protutijela iznad donje granice mjerljivosti imalo 44,7% bolesnika.
At the end of the main study in chronic iron overload due to blood transfusions, 53% of the patients receiving Exjade had shown a sufficient response to treatment, compared with 66% of the patients receiving deferoxamine.
Po završetku glavnog ispitivanja na bolesnicima s kroničnim preopterećenjem željezom zbog transfuzija krvi, 53 % bolesnika koji su primali lijek Exjade pokazalo je dovoljno pozitivan odgovor na liječenje u usporedbi s 66 % bolesnika koji su primali deferoksamin.
At the end of the maintenance treatment an improvement of at least 30% was seen in 57% and 55% of the subjects receiving rotigotine 8 mg/24 h and 12 mg/24 h, respectively and in 34% of the subjects receiving placebo (Differences 22% and 21%, respectively, CI95% 10%; 35% and 8%; 33%, respectively, p<0.001 for both rotigotine groups).
Na kraju terapije održavanja poboljšanje od najmanje 30% zabilježeno je u 57%, odnosno 55% ispitanika koji su primali rotigotin 8 mg/24 h, odnosno 12 mg/24 h te u 34% ispitanika koji su primali placebo (razlike 22%, odnosno 21%; CI95%: 10%, 35%, odnosno 8%, 33%; p<0,001 za obje rotigotin-skupine).
At the end of the maintenance treatment an improvement of at least 30% was seen in 57% and 55% of the subjects receiving rotigotine 8 mg/24 h and 12 mg/24 h, respectively and in 34% of the subjects receiving placebo (Differences 22% and 21%, respectively, CI95% 10%; 35% and 8%; 33%, respectively, p<0.001 for both rotigotine groups).
Na kraju terapije održavanja, poboljšanje od najmanje 30% zabilježeno je u 57%, odnosno 55% ispitanika koji su primali rotigotin 8 mg/24 h, odnosno 12 mg/24 h te u 34% ispitanika koji su primali placebo (razlike 22%, odnosno 21%; CI95%: 10%, 35%, odnosno 8%, 33%; p<0,001 za obje skupine rotigotin-skupine).
At the end of the maintenance treatment an improvement of at least 30% was seen in 60% of the subjects receiving rotigotine, 67% of the subjects receiving pramipexole and 35% of the subjects receiving placebo (Difference rotigotine versus placebo 25%, CI95% 13%; 36%, difference pramipexole versus placebo 32%, CI95% 21%; 43%, difference pramipexole versus rotigotine 7%, CI95% -2%; 17%).
Na kraju terapije održavanja poboljšanje od najmanje 30% zabilježeno je u 60% ispitanika koji su primali rotigotin, 67% ispitanika koji su primali pramipeksol i u 35% ispitanika koji su primali placebo (razlika rotigotin naprama placebo 25%, CI95%: 13%; 36%; razlika pramipeksol naprama placebo 32%, CI95%: 21%, 43%; razlika pramipeksol naprama rotigotin 7%, CI95%: –2%, 17%).
At the end of the maintenance treatment an improvement of at least 30% was seen in 60% of the subjects receiving rotigotine, 67% of the subjects receiving pramipexole and 35% of the subjects receiving placebo (Difference rotigotine versus placebo 25%, CI95% 13%; 36%, difference pramipexole versus placebo 32%, CI95% 21%; 43%, difference pramipexole versus rotigotine 7%, CI95% -2%; 17%).
Na kraju terapije održavanja, poboljšanje od najmanje 30% zabilježeno je u 60% ispitanika koji su primali rotigotin, 67% ispitanika koji su primali pramipeksol i u 35% ispitanika koji su primali placebo (razlika rotigotin naprama placebo 25%, CI95%: 13%; 36%, razlika pramipeksol naprama placebo 32%, CI95%: 21%; 43%, razlika pramipeksol naprama rotigotin 7%, CI95%: –2%; 17%).
At the end of the maintenance treatment an improvement of at least 30% was seen in 60% of the subjects receiving rotigotine, 67% of the subjects receiving pramipexole and 35% of the subjects receiving placebo (Difference rotigotine versus placebo 25%, CI95% 13%; 36%, difference pramipexole versus placebo 32%, CI95% 21%; 43%, difference pramipexole versus rotigotine 7%, CI95% -2%; 17%).
Na kraju terapije održavanja, poboljšanje od najmanje 30% zabilježeno je u 60% ispitanika koji su primali rotigotin, 67% ispitanika koji su primali pramipeksol i u 35% ispitanika koji su primali placebo (razlika rotigotin naprama placebo 25%, CI95%: 13%; 36%; razlika pramipeksol naprama placebo 32%, CI95%: 21%, 43%; razlika pramipeksol naprama rotigotin 7%, CI95%: –2%, 17%).
At the end of the maintenance treatment in 92% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e.
Na kraju terapije održavanja u 92% ispitanika u rotigotin skupini optimalna doza bila je i najveća dozvoljena tj.
At the end of the maintenance treatment in 92% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e.
Na kraju terapije održavanja, u 92% ispitanika u rotigotin skupini optimalna doza bila je i najveća dozvoljena tj.
At the end of the maintenance treatment in 92% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e.
Na kraju terapije održavanja, u 92% ispitanika u rotigotin-skupini optimalna doza bila je i najveća dozvoljena doza tj.
At the end of the maintenance treatment in 92% of the subjects in the rotigotine arm, the optimal dose was the maximal dose allowed i.e.
Na kraju terapije odžavanja, u 92% ispitanika u rotigotin-skupini optimalna doza bila je i najveća dozvoljena doza tj.
At the end of the placebo tablet interval, start the next blister.
Kad završite s razdobljem tableta placeba, počnite uzimati tablete iz sljedećeg blistera.
At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose).
Nakon tri tjedna srednja vrijednost smanjenja krvnog tlaka u odnosu na početne vrijednosti za primarnu varijablu djelotvornosti, sistolički krvni tlak u sjedećem položaju (sjSKT) kod najniže koncentracije u krvi (, iznosila je 11,7 mmHg (niska doza), 9,3 mmHg (srednja doza) i 13,2 mmHg (visoka doza).
At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose).
Nakon tri tjedna srednja vrijednost smanjenja krvnog tlaka u odnosu na početne vrijednosti za primarnu varijablu djelotvornosti, sistolički krvni tlak u sjedećem položaju (sjSKT) kod najniže koncentracije u krvi, iznosila je 11,7 mmHg (niska doza), 9,3 mmHg (srednja doza) i 13,2 mmHg (visoka doza).
At the end of these treat-to-target trials, depending on the patient population and concomitant therapy, a 10-18% higher dose was observed in the Toujeo group than in the comparator group (Table 1 and 2).
Na kraju ovih ispitivanja titracijom do ciljnih vrijednosti (eng. treat-to target trials), ovisno o populaciji bolesnika i popratnoj terapiji, zabilježeno je povećanje doze lijeka u skupini liječenoj lijekom Toujeo za 10-18% u odnosu na usporednu skupinu (Tablica 1 i 2).
At the end of this period of room temperature storage, the product must not be returned to refrigerated storage, but is to be used or discarded.
Na kraju tog razdoblja čuvanja na sobnoj temperaturi lijek se ne smije vratiti u hladnjak, nego se mora primijeniti ili baciti.
At the end of this period the product has to be used or discarded.
Na kraju tog razdoblja lijek se mora upotrijebiti ili baciti.
At the end of this period the product should be used or discarded.
Na kraju tog razdoblja proizvod treba primijeniti ili baciti.
At the end of this period, the product should not be put back in the refrigerator and should be disposed of.
Na kraju tog razdoblja lijek se ne smije vratiti u hladnjak nego ga je potrebno zbrinuti.
At the end of this study, there was no difference in overall hospitalisations for heart failure nor in mortality between bosentan- and placebo- treated patients.
Na kraju studije nije bilo razlike između broja ukupnih hospitalizacija zbog zatajenja srca niti u smrtnosti između bolesnika koji su dobivali bosentan, odnosno placebo.
At the end of treatment, 43% of patients experienced a weight percentile decrease of 15 percentiles or more, and 25% (13 of 53) experienced a height percentile decrease of 15 percentiles or more on the normative growth curves.
Na kraju liječenja je na normativnim krivuljama rasta u 43% bolesnika došlo do smanjenja percentile težine za 15 percentila ili više, a u njih 25% (13 od 53) do smanjenja percentile visine za 15 percentila ili više.
At the end of week 24, 93 patients on hemodialysis whose serum phosphorus levels were controlled (<1.78 mmol/L) with Velphoro in the first part of the study, were re-randomized to continue treatment with either their week 24 maintenance dose (N=44 or a non-effective low dose control 250 mg/day, N=49) of Velphoro for a further 3 weeks.
Po završetku 24. tjedna, 93 bolesnika na hemodijalizi, čije su razine fosfora u serumu bile kontrolirane (<1,78 mmol/l) lijekom Velphoro u prvom dijelu ispitivanja, ponovno su randomizirana da bi u naredna 3 tjedna nastavili terapiju njihovom dozom održavanja iz 24. tjedna (n=44) ili neučinkovitom niskom kontrolnom dozom lijeka Velphoro (250 mg/dan, n=49).
At the end of weekly dosing for the recommended schedule and dose of 16 mg/kg, the mean (SD) serum Cmax value was 915 (410.3) micrograms/mL, approximately 2.9-fold higher than following the first infusion.
Na kraju razdoblja primjene doze od 16 mg/kg jedanput na tjedan prema preporučenom rasporedu, srednja vrijednost (SD) Cmax u serumu iznosila je 915 (410,3) µg/ml, što je približno 2,9 puta više od vrijednosti zabilježene nakon prve infuzije.
At the end of year 2 (12 months after Preotact was discontinued), there was a 12.1 mean increase in dual energy X-ray absorptiometry (DXA) spine BMD for patients who received alendronate for the second year.
Na kraju druge godine (12 mjeseci nakon prekida liječenja Preotactom), zabilježeno je srednje povećanje dvoenergetske apsorpciometrije X-zraka (DXA) kralježnice od 12,1% u bolesnica koje su u drugoj godini uzimale alendronat.
At the end of your treatment you should return all unused capsules.
Na kraju liječenja neiskorištene kapsule morate vratiti.
At the evaluation period (week 29-36), the mean and median level of haemoglobin in patients treated with MIRCERA was virtually identical to their baseline haemoglobin level.
U periodu evaluacije (29. – 36. tjedan praćenja) srednja vrijednost i medijan vrijednosti hemoglobina u bolesnika liječenih lijekom MIRCERA bili su gotovo identični njihovim početnim vrijednostima.
At the event-triggered analysis the efficacy was 92.9% (96.1% CI: 79.9;98.3) against CIN2+ and 80% (96.1% CI: 0.3;98.1) against CIN3+.
Temeljeno na događajem potaknutoj analizi, djelotvornost je bila 92,9% (96,1%-tni CI: 79,9:98,3) na CIN2+, odnosno 80% (96,1%-tni CI: 0,3; 98,1) na CIN3+.
At the event-triggered analysis the efficacy was 92.9% (96.1% CI:79.9;98.3) against CIN2+ and 80% (96.1% CI: 0.3;98.1) against CIN3+.
Temeljeno na događajem potaknutoj analizi, djelotvornost je bila 92,9% (96,1%-tni CI: 79,9:98,3) na CIN2+, odnosno 80% (96,1%-tni CI: 0,3; 98,1) na CIN3+.
At the final analysis, median time to angiomyolipoma progression was not reached.
U završnoj analizi, medijan vremena do progresije angiomiolipoma nije dosegnut.
At the final analysis, the ORR as determined by the investigator’s assessment was 46% (95% CI: 41 - 51) for the sunitinib arm and 12.0% (95% CI: 9 - 16) for the IFN-α arm (p<0.001).
U završnoj je analizi ORR prema procjeni ispitivača iznosio 46% (95% CI: 41-51) u skupini liječenoj sunitinibom te 12,0% (95% CI: 9-16) u skupini koja je primala IFN-α (p < 0,001).
At the final analysis, the skin lesion response rate increased to 58.1% (95% CI: 48.1, 67.7).
Kod završne analize stopa odgovora kožnih lezija povećala se na 58,1% (95% CI: 48,1, 67,7).
At the first occurrence, treatment should be interrupted until resolution, and then resumed at the same dose level;
Kod prve pojave, liječenje treba prekinuti do prestanka nuspojave, a zatim nastaviti na istoj razini doze;
At the first sign or symptom suggestive of PML, withhold Tecfidera and perform appropriate diagnostic evaluations.
Kod prvog znaka ili simptoma koji ukazuje na PML, prekinite primjenu Tecfidere i provedite odgovarajuće dijagnostičke procjene.